Job Opportunities API

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Senior Manager, SEC Reporting and Technical Accounting will be responsible for the preparation and filing of SEC reporting and disclosures, documenting technical accounting matters and ensuring compliance with U.S. GAAP and SEC regulations.  This role will also lead the Company’s  Sabarnes-Oxley (SOX) compliance program, and be involved in complex accounting transactions including accruals, collaboration accounting, and equity accounting. Role and Responsibilities: Participate in the preparation of all external financial reporting, including Forms 10-K/10-Q, earnings releases, proxy statement, and other required SEC filings to ensure accurate and timely reporting in accordance with U.S. GAAP. In conjunction with the Director of SEC Reporting and Technical Accounting, manage the Company's external financial reporting process, including the preparation of financial statements, footnotes, Management's Discussion and Analysis (MD&A), and other required disclosures in accordance with U.S. GAAP and SEC reporting requirements. Preparation of the Statement of Cash Flows, Statement of Shareholder’s equity, Earnings per Share workbooks and other financial disclosure requirements with such filings Coordinate the information gathering process across the organization and interact with the Company’s external auditors Review XBRL interactive data files for all Form 10-Q and 10-K filings in accordance with the SEC filing requirements Research, document memos, record, and communicate technical accounting matters as they arise and journal entries for complex accounting transactions Analyze and interpret new accounting standards and SEC regulations, research and provide appropriate accounting guidance related to various business transactions Research new disclosures and FASB accounting standards updates and work with external auditors on appropriate disclosure requirements Develop, create and